Value of multiparametric MR and MRI-guided biopsies of the prostate in men with an elevated PSA

Phase 3

Recruiting

• Conditions: prostate cancer; prostatic carcinoma; 10014713; 10036958

• Registration Number: NL-OMON39439
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 620

Inclusion Criteria

Men, 50-75 years, PSA > 3 ng/ml

Exclusion Criteria

Use of 5-alfareductase inhibitors
Proven prostate cancer

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint: clinical insignificant versus significant cancers detected. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints: health-related quality of life, accuracy of MR-guided<br /><br>biopsies, cost effectiveness </p><br>